CompanyProfileNomu
Actions
Qomel Co.
- Nomu - Parallel Market
- Health Care Equipment & Svc
Stats Overview
-
Prev. Close 127.20
-
Open -
-
High -
-
Low -
-
No. Of Trades -
-
Avg. Trade size* N/A
-
Volume Traded -
-
Value Traded -
Performance
- *Average Trade Size = Cumulative / # of Trades
- **52 Week Price Change = (Current Price - Price year ago) / Price year ago x 100
- Historical prices & volume traded data are adjusted to account for all corporate actions.
- MO: Market Order
Trade Updates
Trade Updates
Best Bid
Best Offer
52 WEEK
PERFORMANCE
Compare Selected
Select A Maximum Of 5 Companies
LoginPortletPopupv2
Actions
AddtoWatchlistv2
Actions
AnnouncmentandCorporateAction
Actions
- Announcements & Corporate Actions
- Dividends
- Financials
- Shareholding
- Peer Comparison
- Company Profile
Announcements
Corporate Actions
- Announcements & Corporate Actions
- Dividends
- Financials
- Shareholding
- Peer Comparison
- Company Profile
Dividends
| Announced Date | Eligibility Date | Distribution Date | Distribution Way | Dividend Amount |
|---|
CompanyProfileNomuv2Financials
Actions
- Announcements & Corporate Actions
- Financials
- Shareholding
- Peer Comparison
- Company Profile
Financials
- FINANCIAL INFORMATION
- FINANCIAL STATEMENTS AND REPORTS
- Annually
- Semi-Annual
| Balance Sheet | 2023-12-31 | |||
|---|---|---|---|---|
| Total Assets |
99,119
|
- | - | - |
| Total Liabilities |
53,616
|
- | - | - |
| Total Shareholders Equity (After Deducting the Minority Equity) |
45,502
|
- | - | - |
| Total Liabilities and Shareholders Equity |
99,119
|
- | - | - |
| Statement of Income | 2023-12-31 | |||
| Total Revenue (Sales/Operating) |
105,473
|
- | - | - |
| Net Profit (Loss) before Zakat and Tax |
19,037
|
- | - | - |
| Zakat and Income Tax |
-1,443
|
- | - | - |
| Net Profit (Loss) after Zakat and Tax |
17,594
|
- | - | - |
| Total Comprehensive Income |
17,512
|
- | - | - |
| Profit (Loss) per Share |
5.86
|
- | - | - |
| Cash Flows | 2023-12-31 | |||
| Net Cash From Operating Activities |
-4,397
|
- | - | - |
| Net Cash From Investing Activities |
-12,034
|
- | - | - |
| Net Cash From Financing Activities |
2,402
|
- | - | - |
| Cash and Cash Equivalents, Beginning of the Period |
25,405
|
- | - | - |
| Cash and Cash Equivalents, End of the Period |
11,376
|
- | - | - |
| All Figures in | Thousands | |||
| All Currency In | SAR | |||
| Last Update Date | 2024-05-22 |
The Capital Market Authority and Saudi Exchange take no responsibility for the contents of this disclosure, make no representations as to its accuracy or completeness, and expressly disclaim any liability whatsoever for any loss arising from, or incurred in reliance upon, any part of this disclosure, and the issuer accepts full responsibility for the accuracy of the information contained in it and confirms, having made all reasonable enquiries, that to the best of their knowledge and belief, there are no other facts or information the omission of which would make the disclosure misleading, incomplete or inaccurate. The above information does not replace detailed financial statements, as detailed financial statements are the reliable source that must be consulted to obtain accurate financial information.
| Balance Sheet | 2024-06-30 | |||
|---|---|---|---|---|
| Total Assets |
163,793
|
- | - | - |
| Total Liabilities |
69,686
|
- | - | - |
| Total Shareholders Equity (After Deducting the Minority Equity) |
94,108
|
- | - | - |
| Total Liabilities and Shareholders Equity |
163,793
|
- | - | - |
| Statement of Income | 2024-06-30 | |||
| Total Revenue (Sales/Operating) |
58,560
|
- | - | - |
| Net Profit (Loss) before Zakat and Tax |
11,792
|
- | - | - |
| Zakat and Income Tax |
-787
|
- | - | - |
| Net Profit (Loss) after Zakat and Tax |
11,005
|
- | - | - |
| Total Comprehensive Income |
11,005
|
- | - | - |
| Profit (Loss) per Share |
3.52
|
- | - | - |
| Cash Flows | 2024-06-30 | |||
| Net Cash From Operating Activities |
-14,559
|
- | - | - |
| Net Cash From Investing Activities |
-6,389
|
- | - | - |
| Net Cash From Financing Activities |
22,693
|
- | - | - |
| Cash and Cash Equivalents, Beginning of the Period |
11,376
|
- | - | - |
| Cash and Cash Equivalents, End of the Period |
13,122
|
- | - | - |
| All Figures in | Thousands | |||
| All Currency In | SAR | |||
| Last Update Date | 2024-08-12 |
The Capital Market Authority and Saudi Exchange take no responsibility for the contents of this disclosure, make no representations as to its accuracy or completeness, and expressly disclaim any liability whatsoever for any loss arising from, or incurred in reliance upon, any part of this disclosure, and the issuer accepts full responsibility for the accuracy of the information contained in it and confirms, having made all reasonable enquiries, that to the best of their knowledge and belief, there are no other facts or information the omission of which would make the disclosure misleading, incomplete or inaccurate. The above information does not replace detailed financial statements, as detailed financial statements are the reliable source that must be consulted to obtain accurate financial information.
- Announcements & Corporate Actions
- Dividends
- Financials
- Shareholding
- Peer Comparison
- Company Profile
- Announcements & Corporate Actions
- Dividends
- Financials
- Shareholding
- Peer Comparison
- Company Profile
- Announcements & Corporate Actions
- Dividends
- Financials
- Shareholding
- Peer Comparison
- Company Profile
Company Profile
Company overview
Qomel Company offers a variety of services in the healthcare sector, including pharmaceuticals and medical rehabilitation. We currently have distribution agreements with multinational companies for specialized medications and medical devices. The company has also started establishing a subsidiary factory specialized in manufacturing human pharmaceuticals.
Company History
Qomel Company was established in 2007 as a limited liability healthcare company headquartered in Riyadh, Saudi Arabia, with sales offices in Jeddah and Dammam. Additionally, it has three warehouses equipped with state-of-the-art technologies and compliant with the requirements of the Saudi Food and Drug Authority in Riyadh, Dammam, and Jeddah. Qomel obtained all necessary licenses for trading pharmaceuticals and medical supplies in late 2007, with the establishment of a main office and warehouse in Riyadh. Business operations commenced in early 2008
Company Bylaws
Equity Profile
- Authorized Capital (SAR) 35,000,000
- Issued Shares 3,500,000
- Paid Up Capital (SAR) 35,000,000
- Par Value/Share 10
- Paid Up Value/Share 10
Last Update :2024-05-08
Investment limits
There are no restrictions on the company's shares as stated in both the regulations governing the investment of qualified foreign financial institutions in listed securities and the instructions regulating the ownership of strategic stakes by foreign strategic investors in listed companies, in accordance with the company's articles of association and the instructions issued by the supervisory and regulatory authorities to which the company is subject to.
- Company Details
- BOARD OF DIRECTORS AND SENIOR EXECUTIVES INFORMATION
Investor Relations
Contact Name:
Alanoud Yousef Alomani
Company Address:
Al Safwah Commercial Center, Gate # 4, Office # 4107, Sulaymaniyah District, P.O. Box 19811, Riyadh 11445, Saudi Arabia
Contact Details:
Telephone: 00966112886660
Fax: 00966112886668
Email: info@qomel.com
Company Website:
The Capital Market Authority and Saudi Exchange take no responsibility for the contents of these disclosures, make no representations as to its accuracy or completeness, and expressly disclaim any liability whatsoever for any loss arising from, or incurred in reliance upon, any part of these disclosures, and the issuer accepts full responsibility for the accuracy of the information contained in it and confirms, having made all reasonable enquiries, that to the best of their knowledge and belief, there are no other facts or information the omission of which would make the disclosure misleading, incomplete or inaccurate.